AnaptysBio's (ANAB) "Neutral" Rating Reiterated at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of AnaptysBio (NASDAQ:ANAB - Free Report) in a research note published on Tuesday,Benzinga reports. HC Wainwright currently has a $19.00 price objective on the biotechnology company's stock.

ANAB has been the topic of a number of other research reports. Wedbush reaffirmed an "outperform" rating and set a $40.00 target price on shares of AnaptysBio in a research note on Monday. Wells Fargo & Company reduced their price objective on AnaptysBio from $56.00 to $40.00 and set an "overweight" rating on the stock in a research report on Thursday, December 12th. Truist Financial cut their price target on AnaptysBio from $30.00 to $20.00 and set a "hold" rating on the stock in a research note on Wednesday, December 18th. BTIG Research downgraded AnaptysBio from a "buy" rating to a "neutral" rating in a research note on Monday, December 2nd. Finally, UBS Group raised their price objective on shares of AnaptysBio from $23.00 to $33.00 and gave the company a "neutral" rating in a report on Wednesday, October 30th. Four investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, AnaptysBio has an average rating of "Moderate Buy" and an average target price of $40.08.

AnaptysBio Trading Down 9.3 %

AnaptysBio stock traded down $1.50 during midday trading on Tuesday, reaching $14.58. The company's stock had a trading volume of 522,893 shares, compared to its average volume of 700,012. The stock has a market cap of $443.67 million and a PE ratio of -2.40. AnaptysBio has a 52 week low of $12.51 and a 52 week high of $41.31. The business has a 50-day moving average price of $16.69 and a 200-day moving average price of $26.62.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.72) by $0.58. The company had revenue of $30.02 million for the quarter, compared to analyst estimates of $7.92 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. As a group, research analysts predict that AnaptysBio will post -6.08 EPS for the current fiscal year.

Insider Transactions at AnaptysBio

In other AnaptysBio news, Director Ecor1 Capital, Llc bought 65,184 shares of the business's stock in a transaction that occurred on Monday, December 30th. The shares were bought at an average price of $12.92 per share, for a total transaction of $842,177.28. Following the transaction, the director now directly owns 7,860,180 shares in the company, valued at approximately $101,553,525.60. This trade represents a 0.84 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 33.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On AnaptysBio

A number of hedge funds have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. grew its position in shares of AnaptysBio by 11.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company's stock worth $85,000 after buying an additional 644 shares during the period. Algert Global LLC boosted its stake in AnaptysBio by 11.8% during the second quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company's stock worth $255,000 after acquiring an additional 1,078 shares in the last quarter. Rhumbline Advisers grew its holdings in AnaptysBio by 3.8% in the fourth quarter. Rhumbline Advisers now owns 30,077 shares of the biotechnology company's stock worth $398,000 after purchasing an additional 1,111 shares during the period. nVerses Capital LLC increased its stake in AnaptysBio by 700.0% in the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company's stock valued at $54,000 after purchasing an additional 1,400 shares in the last quarter. Finally, Values First Advisors Inc. acquired a new position in shares of AnaptysBio during the third quarter valued at about $49,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.